Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis Chalabi, Y., Peterfy, C., Genovese, M., Emery, P., Taylor, P., Schlichting, D., Beattie, S., Macias, W., Keystone, E. J RHEUMATOL PUBL CO. 2014: 1506

View details for Web of Science ID 000338923700162